DRGs Underpay for Stem Cell Therapy
SAN ANTONIO--Although the literature suggests that peripheral blood stem cell support for hematologic salvage after high-dose chemotherapy is somewhat less expensive than autologous bone marrow transplant (ABMT), the difference is nowhere near the $80,000 disparity found in diagnostic-related group (DRG)-based reimbursement, Philip Bierman, MD, said at a lymphoma symposium sponsored by the University of Texas M.D. Anderson Cancer Center.
SAN ANTONIO--Although the literature suggests that peripheralblood stem cell support for hematologic salvage after high-dosechemotherapy is somewhat less expensive than autologous bone marrowtransplant (ABMT), the difference is nowhere near the $80,000disparity found in diagnostic-related group (DRG)-based reimbursement,Philip Bierman, MD, said at a lymphoma symposium sponsored bythe University of Texas M.D. Anderson Cancer Center.
The DRG allowance for a stem cell transplant for non-Hodgkin'slymphoma patients is $9,880, compared with more than $89,000 forABMT, said Dr. Bierman, associate professor of medicine, Universityof Nebraska. But reports in the literature suggest a differenceof only a few thousand dollars, he said.
Since DRG-based reimbursement is used primarily by Medicare, Medicaid,and Blue Cross/Blue Shield, only a small percentage of transplantsare affected, he said, and he doesn't believe that physiciansor hospitals have allowed the payment difference to influenceclinical decision making. Furthermore, he said, the problem maybe resolved next year when the government reviews the issue.
Axatilimab Induces Rapid and Durable Responses, Is Safe in Recurrent/Refractory cGVHD
December 11th 2023Phase 2 results showed that the investigational monoclonal antibody axatilimab elicited encouraging clinical activity and tolerability across dose levels in patients with recurrent or refractory chronic graft-vs-host disease.
Adapting to a Robotic Workstation for Image-Guided Liver Cancer Surgery
December 4th 2023Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.
Single-Agent Odronextamab Efficacy, Safety Upheld in Relapsed/Refractory DLBCL
December 10th 2023Single-agent treatment with odronextamab continued to demonstrate encouraging clinical activity, along with a manageable safety profile, in patients with relapsed/refractory diffuse large B-cell lymphoma.
Obe-Cel Yields Enduring Responses in Relapsed/Refractory B-ALL
December 10th 2023Treatment outcomes with obecabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia appear to be better in those with lower leukemia burden at lymphodepletion in the FELIX study.
Auto-HCT Improves PFS and Reduces Relapses in LBCL in Complete Remission
December 10th 2023Auto-HCT results in higher overall survival compared with CAR-T cell therapy in patients with relapsed large B-cell lymphoma while they are in complete response, according to findings from a retrospective study.
